Winlevi (Clascoterone) Patent Expiration, LOE Window & CMS Spending

Winlevi (Clascoterone) by Sun Pharmaceutical: FDA Orange Book core substance LOE 2031-08-26, 0 AB generics, $20.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN213433 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-08-26
Last Listed Patent or Exclusivity Date2031-08-26
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20.2M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$19.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel